14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 MDGL stock ended at $229.84. This is 6.38% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 5.88% from a day low at $221.25 to a day high of $234.25.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Jul 19, 2023 $220.99 $222.46 $212.67 $216.76 188 237
Jul 18, 2023 $222.49 $224.26 $217.74 $219.32 163 140
Jul 17, 2023 $228.50 $239.76 $222.30 $223.03 226 263
Jul 14, 2023 $225.46 $226.26 $218.09 $225.77 125 239
Jul 13, 2023 $221.38 $228.79 $220.15 $224.55 168 691
Jul 12, 2023 $222.76 $225.16 $218.78 $220.48 207 268
Jul 11, 2023 $217.35 $222.97 $215.36 $221.12 136 570
Jul 10, 2023 $218.99 $224.72 $218.99 $220.09 236 587
Jul 07, 2023 $220.28 $222.80 $216.16 $219.13 177 775
Jul 06, 2023 $219.33 $222.08 $216.04 $220.53 202 960
Jul 05, 2023 $226.00 $229.77 $221.01 $221.09 212 737
Jul 03, 2023 $228.89 $231.64 $223.38 $225.78 201 276
Jun 30, 2023 $222.07 $233.16 $220.35 $231.00 483 406
Jun 29, 2023 $220.15 $223.18 $215.15 $220.21 331 813
Jun 28, 2023 $207.10 $223.23 $205.10 $221.68 1 039 212
Jun 27, 2023 $230.54 $230.54 $192.23 $203.88 1 823 648
Jun 26, 2023 $242.17 $243.40 $233.50 $235.22 455 311
Jun 23, 2023 $241.11 $241.65 $232.12 $237.67 507 296
Jun 22, 2023 $241.00 $257.26 $239.00 $243.40 732 897
Jun 21, 2023 $243.73 $243.75 $236.45 $240.89 377 210
Jun 20, 2023 $257.90 $257.99 $239.04 $245.47 576 363
Jun 16, 2023 $257.11 $257.11 $242.98 $244.09 467 724
Jun 15, 2023 $255.00 $257.87 $251.59 $255.53 208 712
Jun 14, 2023 $268.00 $268.71 $255.10 $256.71 321 533
Jun 13, 2023 $266.14 $270.75 $265.25 $268.42 133 969
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT